Trial Profile

Effect of urate LowEring Agent Febuxostat in Chronic Heart Failure patients with hyperuricemia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Febuxostat (Primary)
Indications Chronic heart failure; Hyperuricaemia
Focus Therapeutic Use
Acronyms LEAF-CHF

Most Recent Events

01 Feb 2025 Results assessing the efficacy and the safety of febuxostat treatment in hyperuricemic CHF patients with reduced left ventricular ejection fraction , published in the Heart and Vessels
28 Feb 2019 Status changed from recruiting to completed.
05 Mar 2015 According to the the University Hospital Medical Information Network - Japan record, status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com